Antiviral treatment selection for SARS-CoV-2 pneumonia

References

• Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. 2020 Dec;8(12):1201–1208. .
   PubMed Web of Science ®Google Scholar
• Robba C, Battaglini D, Ball L, et al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol. 2020 Aug;279:103455.
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Di Biagio A, et al. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clin Microbiol Infect. 2020 Nov;26(11):1537–1544. .
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Silva PL, Cruz FF, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. 2021 Jan 28;12:593223. .
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Aliberti S, et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020 Jul;26(7):880–894. .
   PubMed Web of Science ®Google Scholar
• Bassetti M, Pelosi P, Robba C, et al. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic. Drugs Context. 2020;9:9.
   Google Scholar
• Ac K. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020 May 19;323(19):1897–1898.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang XJ. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020 Feb 20;47(2):119–121.
   PubMed Web of Science ®Google Scholar
• Nukoolkarn V, Lee VS, Malaisree M, et al. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008 Oct 21;254(4):861–867.
   PubMed Web of Science ®Google Scholar
• Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003 Dec;9(6):399–406.
   PubMedGoogle Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252–256. .
   PubMed Web of Science ®Google Scholar
• Park SJ, Yu KM, Kim YI, et al. Antiviral efficacies of FDA-Approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020 May 22;11(3):3.
   Web of Science ®Google Scholar
• Zuo Y, Liu Y, Zhong Q, et al. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China. J Med Virol. 2020 Nov;92(11):2666–2674. .
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang M, Shin SY, et al. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: a nationwide propensity score-matched cohort study. Int J Infect Dis. 2020 Oct 27;102:275–281. .
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct;396:1345–1352.
   Google Scholar
• World Health Organization (WHO). Therapeutics and COVID-19: living guideline, 31 March 2021. Geneva: World Health Organization; 2020.
   Google Scholar
• Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917–921. .
   PubMed Web of Science ®Google Scholar
• Boriskin YS, Leneva IA, Pecheur EI, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997–1005. .
   PubMed Web of Science ®Google Scholar
• Brooks MJ, Burtseva EI, Ellery PJ, et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol. 2012 Jan;84(1):170–181. .
   PubMed Web of Science ®Google Scholar
• Khamitov RA, Loginova S, Shchukina VN, et al. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol. 2008 Jul-Aug;53(4):9–13.
   PubMedGoogle Scholar
• Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6(1):28. .
   Web of Science ®Google Scholar
• Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020 Dec 14;20(1):954.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Favipiravir NT. (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271. .
   PubMed Web of Science ®Google Scholar
• Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa1176.
   Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020 Oct;6(10):1192–1198. .
   PubMedGoogle Scholar
• Kocayigit H, Ozmen Suner K, Tomak Y, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. J Clin Pharm Ther. 2020 Oct;46(2):31. .
   Web of Science ®Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2020 Nov 16;103:62–71. .
   PubMed Web of Science ®Google Scholar
• Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2020 Nov 9;102:538–543. .
   PubMed Web of Science ®Google Scholar
• Nili A, Farbod A, Neishabouri A, et al. Remdesivir: a beacon of hope from Ebola virus disease to COVID-19. Rev Med Virol. 2020 Nov;30(6):1–13. .
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396). DOI:10.1126/scitranslmed.aal3653.
   PubMed Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020 Sep;585(7824):273–276. .
   PubMed Web of Science ®Google Scholar
• Borbone N, Piccialli G, Roviello GN, et al. Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other Coronaviruses. Molecules. 2021 Feb 13;26(4):986.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020 Nov 5;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 Nov 5;383(19):1827–1837.
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020 Sep 15;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511.
   PubMed Web of Science ®Google Scholar
• Gasmi A, Peana M, Noor S, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Appl Microbiol Biotechnol. 2021 Jan;105(4):30. .
   Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. .
   PubMed Web of Science ®Google Scholar
• Gao G, Wang A, Wang S, et al. Brief report: retrospective evaluation on the efficacy of lopinavir/ritonavir and chloroquine to treat nonsevere COVID-19 Patients. J Acquir Immune Defic Syndr. 2020 Oct 1;85(2):239–243.
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational Study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Jun 18;382(25):2411–2418.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020 Jun 23;323(24):2493–2502.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020 Oct;103(4):1635–1639. .
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030–2040.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Jan;27(1):19–27. .
   PubMed Web of Science ®Google Scholar
• Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2021 Jan 1;76(1):30–42.
   PubMed Web of Science ®Google Scholar
• Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020 Oct 20;11(1):5284.
   PubMed Web of Science ®Google Scholar
• Mitja O, Corbacho-Monne M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa1009.
   Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May;14(369):m1849. .
   Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021. DOI: 10.1038/s41577-021-00542-x.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135.
   Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021 Feb 16;325(7):632–644.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Rizk JG, Kalantar-Zadeh K, Mehra MR, et al. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020 Sep;80(13):1267–1292. .
   PubMed Web of Science ®Google Scholar
• Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196–206. .
   PubMed Web of Science ®Google Scholar
• Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020 Jul 15;253:117592. .
   PubMed Web of Science ®Google Scholar
• Kim J, Zhang J, Cha Y, et al. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). J Transl Med. 2020 Jun 25;18(1):257.
   PubMed Web of Science ®Google Scholar
• Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020 Nov 1;75(11):3373–3378.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020 Nov 1;75(11):3379–3385.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao Y, Hu W, et al. Treatment of COVID-19 patients with prolonged post-symptomatic viral shedding with leflunomide – a single-center, randomized, controlled clinical trial. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa1417.
   Google Scholar
• Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: a randomized, open-label, parallel-group trial. Int J Infect Dis. 2020 Oct;99:84–91.
   PubMed Web of Science ®Google Scholar
• Bleyzac N, Goutelle S, Bourguignon L, et al. Azithromycin for COVID‑19: more than just an antimicrobial? Clin Drug Investig. 2020 Aug;40(8):683–686.
   PubMed Web of Science ®Google Scholar
• PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Mar 20; 397(10279):1063–1074. .
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhang X, Yang Y, et al. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 Dec;4(12):1134–1139
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048. .
   PubMed Web of Science ®Google Scholar